Linezolid and Anemia in Children with Tuberculosis
Author Information
Author(s): Brooks Jordan T, Solans Belén P, Béranger Agathe, Schaaf H Simon, van der Laan Louvina, Sharma Sangeeta, Furin Jennifer, Draper Heather R, Hesseling Anneke C, Garcia-Prats Anthony J, Savic Radojka M
Primary Institution: University of California–San Francisco
Hypothesis
What are the pharmacokinetic risk factors for anemia in children treated for rifampicin-resistant tuberculosis?
Conclusion
The study confirms that current linezolid doses for children are appropriate, but children with low baseline hemoglobin are at higher risk of developing anemia.
Supporting Evidence
- Linezolid is classified as a priority drug for RR/MDR-TB treatment by WHO.
- Anemia events were frequent, with 46.4% of participants experiencing at least one.
- Baseline hemoglobin was the main predictor of developing anemia.
- Children with low baseline hemoglobin had a higher risk of severe anemia.
Takeaway
This study shows that children taking a medicine called linezolid for tuberculosis need to be careful if they have low blood levels, as it can make them very sick.
Methodology
The study evaluated linezolid pharmacokinetics and hemoglobin data in a cohort of children treated for RR/MDR-TB, using nonlinear mixed effects modeling and multivariable ordinal logistic regression.
Potential Biases
Potential bias due to the small number of participants with HIV and the timing of hemoglobin measurements.
Limitations
Data were limited to children from South Africa and India, and not all baseline hemoglobin data were true pre-linezolid initiation.
Participant Demographics
Children aged 0–17 years from South Africa and India, with a median age of 7.2 years.
Statistical Information
P-Value
0.0136
Confidence Interval
95% CI, 1.98–3.62
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website